Why placebo trials for #MECFS & #LongCovid? It’s how drugs get approved, and we have none. Placebo trials change medicine. We'll compare RAPAMYCIN with placebo, and all will receive treatment. We seek to prove which subset responds and change medicine, finally. www.simmaronresearch.com/donate

Watch! Dr. Avik Roy & Dr. Gunnar Gottschalk of Simmaron Research Foundation share how six years of work on the molecular mechanisms of #MECFS has led to one of the only ongoing clinical trials specifically designed around a defined biological target. https://youtu.be/OMmjcTKxivU#MECFS#MEAwarenessHour

#ME & #LongCovid have no FDA approval, no successful placebo-controlled trial, no accepted biomarker. Our placebo-controlled rapamycin trial is a strategic opportunity for change. Read how testing biomarkers with treatment holds so much promise: simmaronresearch.salsalabs.org/placebotrial #MECFS

Why low-dose rapamycin? It regulates mTOR & autophagy, pathways that may be disrupted in #MECFS & #LongCOVID. Our placebo-controlled trial measures biomarkers, immune signaling, and metabolics to learn why some improve, and who is likely to. Help us prove it. DONATE: www.simmaronresearch.com/donate

Our placebo-controlled trial will pay for the costs of rapamycin, placebo, safety tests, biomarker tests and clinical work, to ease patient burden & so results aren’t influenced by costs. A generous donor will double your gift! Help prove treatments for #ME #LongCovid www.simmaronresearch.com/donate

1️⃣ #MECFS and #LongCOVID affect millions worldwide — yet no @FDA approved treatment exists. 2️⃣ Our team at Simmaron Research is studying low-dose rapamycin, a drug that regulates cellular pathways involved in inflammation and autophagy. Thread 🧵1/4

Our new placebo-controlled rapamycin trial is based on 4 publications of our work on mechanisms & biomarkers disrupting autophagy in a subset of #MECFS & #Longcovid. Phase 1 of our treatment & biomarker trial was published in Jnl of Translational Medicine: link.springer.com/article/10.1.... 1/4🧵

We’re launching a placebo-controlled study of rapamycin for #MECFS and #LongCOVID. Early data from our Phase II trial shows promise — now we must test it under rigorous blinded conditions. Help us make it happen. Donate to support the study. www.simmaronresearch.com/donate #ME #Rapamycin